Trop2: Jack of All Trades, Master of None

Investor logo
Investor logo
Investor logo

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Science. Official publication website can be found on muni.cz.
Authors

LENÁRT Sára LENÁRT Peter ŠMARDA Jan REMŠÍK Ján SOUČEK Karel BENEŠ Petr

Year of publication 2020
Type Article in Periodical
Magazine / Source Cancers
MU Faculty or unit

Faculty of Science

Citation
Web https://doi.org/10.3390/cancers12113328
Doi http://dx.doi.org/10.3390/cancers12113328
Keywords Trop2; TACSTD2; cancer; proliferation; metastases; epithelial-to-mesenchymal transition; therapy
Attached files
Description Trophoblast cell surface antigen 2 (Trop2) is a widely expressed glycoprotein and an epithelial cell adhesion molecule (EpCAM) family member. Although initially identified as a transmembrane protein, other subcellular localizations and processed forms were described. Its congenital mutations cause a gelatinous drop-like corneal dystrophy, a disease characterized by loss of barrier function in corneal epithelial cells. Trop2 is considered a stem cell marker and its expression associates with regenerative capacity in various tissues. Trop2 overexpression was described in tumors of different origins; however, functional studies revealed both oncogenic and tumor suppressor roles. Nevertheless, therapeutic potential of Trop2 was recognized and clinical studies with drug-antibody conjugates have been initiated in various cancer types. One of these agents, sacituzumab govitecan, has been recently granted an accelerated approval for therapy of metastatic triple-negative breast cancer. In this article, we review the current knowledge about the yet controversial function of Trop2 in homeostasis and pathology.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.